Tiziana Life Sciences is trading 12.19% up at $1.07 after requesting FDA orphan drug designation for intranasal foralumab to treat multiple system atrophy. - The company announced the request on September 30, 2026; supplied alert context reported shares up 8% after the news. - The FDA aims to review requests within 90 days; this is not an approval. If granted, designation could offer market exclusivity upon approval and certain development incentives.